Companies:
50,306
Total Market Cap:
142238746626401.63
Global Rank
#28256
Country Rank
#1518
Market Cap
64.12 M
Price
1.89
Change (%)
0.00%
Volume
37,071
SCL Science's latest marketcap:
64.12 M
As of 08/11/2025, SCL Science's market capitalization has reached $64.12 M. According to our data, SCL Science is the 28256th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 64.12 M |
| Revenue (ttm) | 4.22 M |
| Net Income (ttm) | -3,400,958.51 |
| Shares Out | 33.97 M |
| EPS (ttm) | -0.12 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/12/2025 |
Market Cap Chart
Data Updated: 08/11/2025
SCL Science's yearly market capitalization.
SCL Science has seen its market value grow from ₩69.61 B to ₩89.18 B since 2019, representing a total increase of 28.11% and an annual compound growth rate (CAGR) of 4.51%.
| Date | Market Cap(₩) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/11/2025 | ₩89.18 B | $64.12 M | 48.59% | 28256 |
| 12/30/2024 | ₩60.02 B | $40.21 M | -6.5% | 29507 |
| 12/28/2023 | ₩64.19 B | $49.43 M | 33.91% | 27830 |
| 12/29/2022 | ₩47.93 B | $37.87 M | -21.46% | 28766 |
| 12/30/2021 | ₩61.03 B | $51.27 M | -26.89% | 27379 |
| 12/30/2020 | ₩83.48 B | $76.8 M | 19.93% | 22168 |
| 12/30/2019 | ₩69.61 B | $59.86 M | 20903 |
Company Profile
About SCL Science Inc.
SCL Science Inc. is a medical technology company specializing in advanced hemostatic agents developed using biomimetic innovation. Formerly known as InnoTherapy, Inc., the company rebranded to SCL Science Inc. in March 2024.
Key Products & Solutions
- BiMM (Bio-inspired Medical Materials): Rapid blood-reactive hemostatic agent.
- Endoseal: Designed for gastrointestinal bleeding control.
- InnoSeal: Versatile hemostatic agent for cardiology, radiology, and neurosurgery.
- Jelly Seal: Dual-action hemostasis and sealing product.
- STOP: Prevents intravascular injection-related bleeding.
- Film: Leakage prevention at intestinal and vascular anastomosis sites.
- InnoLOCK & InTro: Vascular interventional procedure tools.
Additional Services
Beyond product development, SCL Science Inc. offers:
- Clinical trial analysis for new drug development.
- Performance evaluation of in vitro diagnostic devices.
- Bio-logistics, including pharmaceutical and clinical sample transportation.
Founded: 2010 | Headquarters: Seoul, South Korea
Frequently Asked Questions
-
What is SCL Science's (KOSDAQ-246960) current market cap?As of 08/11/2025, SCL Science (including the parent company, if applicable) has an estimated market capitalization of $64.12 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does SCL Science (KOSDAQ-246960) rank globally by market cap?SCL Science global market capitalization ranking is approximately 28256 as of 08/11/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.